Cargando…

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial

BACKGROUND: In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current recommendations, based on expert opinion, are that patients should be treated for a minimum of 20 months. A series of cohort...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nunn, Andrew J, Rusen, ID, Van Deun, Armand, Torrea, Gabriela, Phillips, Patrick PJ, Chiang, Chen-Yuan, Squire, S Bertel, Madan, Jason, Meredith, Sarah K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164715/ https://www.ncbi.nlm.nih.gov/pubmed/25199531 http://dx.doi.org/10.1186/1745-6215-15-353

Ejemplares similares

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
por: Goodall, Ruth L, et al.
Publicado: (2022)

Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial
por: Madan, Jason J, et al.
Publicado: (2020)

Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol
por: Gama, Elvis, et al.
Publicado: (2016)

Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis
por: Goodall, Ruth L., et al.
Publicado: (2022)

Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
por: Phillips, P. P. J., et al.
Publicado: (2020)

Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial
por: Rosu, Laura, et al.
Publicado: (2020)

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence
por: Trébucq, Arnaud, et al.
Publicado: (2019)

Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis
por: Grace, Angeline G, et al.
Publicado: (2019)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen
por: Lempens, Pauline, et al.
Publicado: (2020)

Outcomes associated with standardized treatment regimens for extensively drug-resistant tuberculosis
por: Aggarwal, Anivita, et al.
Publicado: (2020)

Poor outcomes in recurrent tuberculosis: More than just drug resistance?
por: Cohen, Danielle B., et al.
Publicado: (2019)

QT prolongation in the STREAM Stage 1 Trial
por: Hughes, G., et al.
Publicado: (2022)

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Decroo, Tom, et al.
Publicado: (2020)

Challenges in Tuberculosis Clinical Trials in the Face of the COVID-19 Pandemic: A Sponsor’s Perspective
por: Rusen, I.D.
Publicado: (2020)

Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review
por: Mallick, Jahan Saeed, et al.
Publicado: (2022)

Drug resistance of Mycobacterium tuberculosis in Malawi: a cross-sectional survey
por: Abouyannis, Michael, et al.
Publicado: (2014)

Routine surveillance for the identification of drug resistant Tuberculosis in Tanzania: A cross-sectional study of stakeholders’ perceptions
por: Doulla, Basra Esmail, et al.
Publicado: (2019)

Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation
por: Souleymane, Mahamadou Bassirou, et al.
Publicado: (2022)

Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis
por: Kwon, Yong-Soo
Publicado: (2017)

Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results
por: Ng, Kamela Charmaine, et al.
Publicado: (2018)

Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis
por: Coeck, Nele, et al.
Publicado: (2016)

New anti-tuberculosis drugs and regimens: 2015 update
por: D'Ambrosio, Lia, et al.
Publicado: (2015)

Designing molecular diagnostics for current tuberculosis drug regimens
por: Georghiou, Sophia B., et al.
Publicado: (2023)

Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes
por: Decroo, Tom, et al.
Publicado: (2020)

Multi Drug Resistant Tuberculosis in Mosango, a Rural Area in the Democratic Republic of Congo
por: Kaswa, Michel Kayomo, et al.
Publicado: (2014)

Treatment-shortening regimens for tuberculosis: updates and future priorities
por: Saluzzo, Francesca, et al.
Publicado: (2023)

What can dissaving tell us about catastrophic costs? Linear and logistic regression analysis of the relationship between patient costs and financial coping strategies adopted by tuberculosis patients in Bangladesh, Tanzania and Bangalore, India
por: Madan, Jason, et al.
Publicado: (2015)

A systematic assessment of the concept and practice of public-private mix for tuberculosis care and control
por: Malmborg, Rasmus, et al.
Publicado: (2011)

Protocol for the Addressing the Social Determinants and Consequences of Tuberculosis in Nepal (ASCOT) pilot trial
por: Rai, Bhola, et al.
Publicado: (2022)

Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
por: Van Deun, Armand, et al.
Publicado: (2021)

Worldwide Emergence of Extensively Drug-resistant Tuberculosis
por: Shah, N. Sarita, et al.
Publicado: (2007)

Implementation of a national anti-tuberculosis drug resistance survey in Tanzania
por: Chonde, Timothy M, et al.
Publicado: (2008)

Drug-resistant tuberculosis: Progress towards shorter and safer regimens
por: Saravu, Kavitha, et al.
Publicado: (2019)

The pipeline of new molecules and regimens against drug-resistant tuberculosis
por: Black, Todd A., et al.
Publicado: (2021)

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets
por: Alsayed, Shahinda S. R., et al.
Publicado: (2023)

Case-Finding Strategies for Drug-Resistant Tuberculosis: Protocol for a Scoping Review
por: Van Wyk, Susanna S, et al.
Publicado: (2022)

Drug-resistant tuberculosis: Promising progress with a note of caution
por: Esmail, Hanif, et al.
Publicado: (2022)

Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens
por: Budak, Maral, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b26fja0ibs7g6vanknb0pvudhg